Bluebird’s star gene therapy patient still doing well after 15 months-plus; Takeda, Arix partner on biotech startups – Endpoints News
Endpoints News |
Bluebird’s star gene therapy patient still doing well after 15 months-plus; Takeda, Arix partner on biotech startups
Endpoints News Patient 1204 in bluebird’s program for LentiGlobin gene therapy program has had more than 15 months of followup, and his physicians say that the teenager has been free of the painful symptoms of sickle cell disease, able to lead a normal life and stop … |
Ruidoso News |
Keithley’s Korner: Big benefits from Stem Cell Therapy
Ruidoso News “It obviously wasn’t going to heal itself, so we had Tim come in and consider stem cell therapy,” Dr. Rath said. “It turns out that we were able to help his body heal itself without putting him through painful knee surgery.” Within a day after the … |
Genetic Engineering & Biotechnology News |
Immunotherapy Thwarted by Mutational Load, Copy Loss Combo
Genetic Engineering & Biotechnology News Immune checkpoint blockade, a therapy intended to boost the T-cell response to cancer, doesn’t always work, for reasons that aren’t always clear. If the reasons were better understood, this form of immunotherapy could become more effective. Ultimately … |
Genetic Literacy Project |
Stanford Team Develops Targeted STR Sequencing Approach That Harnesses CRISPR-Cas9
GenomeWeb NEW YORK (GenomeWeb) – Researchers from Stanford University have developed a targeted sequencing approach for microsatellites that makes use of the CRISPR-Cas9 system to selectively fragment DNA. In a study published in Nature Communications … ‘Superbugs’ could be killed with ‘genetic chainsaw’ version of gene editor CRISPRGenetic Literacy Project Genome editing: Pressing the ‘delete’ button on DNAPhys.Org Scientists Have Created A Way to “Delete” DNA in Living CellsFuturism |
|
Complete Cpf1-Based CRISPR Genome Editing System Available
Labmate Online Integrated DNA Technologies (IDT) is the first genomics company to develop and bring to market a complete ribonucleoprotein-based Cpf1 CRISPR system. The Alt-R™ A.s. Cpf1 CRISPR System inherits the optimised, efficient, and cost-effective traits of … |
WND.com |
Gene therapy leaves terminal cancer patients in complete remission
WND.com (London Telegraph) A groundbreaking gene therapy treatment which boosts a patient’s own immune cells has been shown to clear disease from one third of terminal patients. US pharmaceutical company Kite Pharma released results from the first six months … A New Cancer Treatment Has Given Terminal Patients a Second Chance at LifeFuturism Global Personalized Gene Therapy Treatments For Cancer Industry 2016 Market Research & AnalysisMedgadget (blog) |